Tactile Systems Technology, Inc. (TCMD) Earnings Call Transcript
August 10, 2026
Earnings Call Speaker Segments
Good afternoon, and thanks for being with us on today's call. Joining me from Tactile's management team are Sheri Dodd, our Chief Executive Officer, and Elaine Birkemeyer, our Chief Financial Officer. Before we get started, I want to remind everybody that what we say today, along with our answers to your questions, might include forward-looking statements. These are based on management's present expectations and carry inherent risks and uncertainties. Actual results could end up differing materially from what those statements indicate, including the ones described in the Risk Factors section of our annual report on Form 10-K, and in our latest 10-Q filing to be filed with the Securities and Exchange Commission. Those factors might be updated periodically in our SEC filings, which you can find on our website. We assume no duty to publicly update or revise any forward-looking statements, whether because of new information, future events, or anything else. Today's call will also mention certain financial measures that aren't calculated in accordance with Generally Accepted Accounting Principles, or GAAP; we typically call these non-GAAP financial measures. Reconciliations between those non-GAAP financial measures and the most comparable measures calculated and presented in accordance with GAAP can be found in the earnings press release on the investor relations portion of our website. With that, I'll hand the call over to Sheri.
Thank you, Sam. Hello, everybody, and thanks for joining us for the Second Quarter 2026 Earnings Call. Joining me today is Elaine Birkemeyer, who serves as our Chief Financial Officer. We turned in yet another robust quarter of execution during Q2, distinguished by ongoing momentum in our lymphedema business and substantial growth in profitability. Revenue on a total basis came in at $85.7 million, representing a 9% increase compared with the same period last year, while lymphedema delivered $73.6 million, which was up 12% versus a year ago. AffloVest brought in $12.1 million, which reflects a 7% decrease from the prior-year period, attributable to short-term inventory management dynamics among a number of our large DME partners tied to the launch of our next generation AffloVest system that took place during the quarter. Notably, measured on a trailing 12-month basis, AffloVest revenue continues to be up 32% compared with last year, which speaks to how durable the underlying growth trend is, even while we navigate this near-term dynamic that I will address shortly. Alongside our solid revenue results, we posted another quarter of substantial profitability growth. Gross margin rose 180 basis points versus the prior year and adjusted 49% to $11.4 million, which mirrors both operating leverage and disciplined execution throughout the business. We remain strategic and measured when it comes to capital allocation, finishing the second quarter with roughly $70 million in cash. Our cash balance sheet is robust, which gives us flexibility to put capital into growth and return capital to shareholders across the short, medium, and long-term horizons. Given how we performed in the first half, we are revising our full year 2026 revenue guidance to a range of $360 million-$366 million. Inside that outlook, we expect sustained strength in revenue expectations for the lymphedema business, while taking a more conservative view of ordering patterns in our airway clearance business as certain DME partners work through inventory while converting to the next generation AffloVest system. I will now walk through our second quarter performance by business line and share updates on our ongoing strategic priorities. Elaine will then cover our financial results in more detail and offer additional perspectives regarding our outlook for the remainder of 2026. The lymphedema market and our lymphedema business are both healthy, and we are glad to see the ongoing growth momentum reflected in a 12% year-over-year revenue growth in Q2. As we have mentioned previously, our sales organization calls on a range of payer types, such as vascular and oncology practices, lymphatic therapists, and the VA, each of which typically serves different patient needs. Consequently, our revenue mix across payer types, Medicare, commercial, and VA, naturally reflects these points and is further shaped by the unique coverage policy dynamics. Since aligning our documentation criteria with the now stable Medicare NCD policy, we keep seeing increasing volume of Flexitouch orders, driven in part by our large number of Medicare patients accessing advanced pump therapy more directly than was permitted under the previous LCD policy. That expansion got partly counterbalanced by the Medicare prior authorization mandate that took effect April 13th. It added more administrative hoops to the ordering workflow and led to some short-term softening in Medicare order volumes across the quarter, even though adoption of Flexitouch keeps rising on its own. For these patients, the interval between finishing an order and shipping it is a bit longer now, but approval rates for prior authorization and adjudication timeframes have come in as we anticipated. We acted fast to get ready for these mandates before the April 13th start date and began the quarter in a strong position to carry out the new prior authorization procedure. Now that a full quarter of experience is behind us, we anticipate the early effects of the rollout will ease and operational efficiency will keep getting better as our teams and the MACs become more accustomed to the new mandates. Our commercial revenue mix keeps showing sustained growth, driven by patient demand, product therapy options, and sales execution across the provider and clinician channels. Although coverage policies differ among commercial payers, we still observe wide access to our therapies. Our work stays centered on cutting administrative burden and broadening patient access in places where payer mandates or coverage restrictions have yet to catch up with the expanding body of clinical evidence, society-based guidelines, and current standards of care. When it comes to the VA, revenue performance there shows less quarter-to-quarter variability thanks to the steady reimbursement environment and a more streamlined operating model; we still see the VA as a strategic long-term opportunity given the breadth of providers and patient needs. On that note, we're genuinely thrilled about our recently announced distribution agreement with ElastiMed to deliver a novel compression therapy device specifically to veterans, active duty service members, and other beneficiaries served through the Department of Defense; we think this opportunity will add incremental growth within the VA channel over time by broadening the range of treatment options available to patients and clinicians. I'll return to this partnership in greater detail shortly when we talk about our strategic initiatives. Now shifting to airway clearance. As I noted, AffloVest sales fell 7% year-over-year in the second quarter, which reflects temporary inventory management dynamics among several of our large DME partners tied to the launch of our next generation AffloVest system during the quarter. As we coordinated closely with the DMEs regarding the launch of our next generation AffloVest system, we found out that a few larger partners had been holding elevated AffloVest inventory levels. We anticipate this will temper purchasing activity among these specific organizations as they work through existing inventory. As many of you are aware, this kind of inventory management dynamic is typical among DMEs. Given what we can see today, we expect these inventory management dynamics to keep shaping ordering patterns through the third quarter, with purchasing activity starting to normalize in the fourth quarter as their inventory levels rebalance. The underlying fundamentals of this business remain strong. Patient demand, the coverage landscape, and where AffloVest sits competitively all look good. In its market, AffloVest stands out as a differentiated offering occupying a leadership role, backed by solid DME relationships and a sizable addressable opportunity. Looking at a trailing 12-month basis, AffloVest revenue rose at a compound annual rate of roughly 28% across the last two years, and on that same TTM basis it's still up 32% year-over-year in Q2. That highlights how durable the underlying growth trend is, even with the near-term inventory management dynamics tied to launching our next generation AffloVest system this quarter. Notably, airway clearance continues to be a profitable contributor to our business. We're confident the recently launched next generation AffloVest system will keep strengthening our category leadership position in high-frequency chest wall oscillation and stay the product of choice for DME partners, clinicians, and the patients they serve. Now shifting to an update on LymphaTech. In our view, this acquisition tackles two of the most significant unmet needs in the lymphedema patient journey. Earlier and more objective diagnosis plus monitoring of disease progression, and the ability to personalize therapy to a patient's specific clinical needs over time. Beginning with diagnosis. Lymphedema is a chronic progressive disease that's largely diagnosed and monitored today through clinician evaluation, including girth measurement and patient-reported symptoms, inputs that are hard to standardize and unreliable for early detection. There are 20 million patients in the U.S.
There are people living with lymphedema who have never received a diagnosis, and reaching that group represents meaningful growth potential for our company and, even more crucially, for the care those patients receive. The FDA-cleared offering from LymphaTech tackles this undiagnosed population challenge head-on by delivering objective, quantitative measurement of limb volume and circumference, along with a clinical-grade 3D model of the impacted anatomy. Clinicians gain a clear picture of how the disease is progressing, and patients get a visual grasp of their own condition — something we believe drives stronger engagement and helps them obtain therapy sooner. Right now, LymphaTech is sold as a SaaS offering, and it's used mostly in oncology centers, where clinicians rely on it to establish patient baselines and monitor how things change over time. But there's a much larger opportunity ahead: expanding what LymphaTech can do as a diagnostic aid specifically, which would help address the gap for the millions of undiagnosed patients I mentioned earlier. Since we lead this market, our aim is to be the first to begin supporting physicians with these diagnostic needs and the complex patients they treat. To that end, we've submitted for a broader indication as a diagnostic aid for lymphedema, and we expect FDA approval in 2027. Simultaneously, we're advancing our work toward securing a Category III CPT code, since that would open up a reimbursement route and allow broader uptake down the road. Turning to what's ahead, LymphaTech also expands our R&D reach to address the second unmet need — building sensing and measurement directly into personalized therapy delivery, so that treatment can be tailored over time to this patient's specific lymphatic care requirements. Integration work continues to move ahead, and early input from clinicians has strengthened our confidence in these key strategic opportunities on the horizon. We'll provide further updates as we make headway on commercialization, reimbursement, and product development efforts. Continued execution of our three ongoing strategic priorities served as the foundation for our Q2 performance. We're working on three things: making it easier for patients to get care, broadening the treatments available to them, and increasing what a patient is worth to us over their whole time with us. Let's begin with getting patients in the door. As we've said, we've concentrated on efforts both inside and outside the company that target removing obstacles and points of friction patients encounter as they move through their care journey. Looking at this from the outside, better market access comes from generating clinical evidence, getting guidelines out there, and talking with both government and commercial payers. On the clinical evidence side, I'm happy to report today that the six-month manuscript from our Head and Neck Clinical Evidence Program has come out in the "International Journal of Radiation Oncology • Biology • Physics." This trial involved 236 patients at 10 sites, making it the biggest randomized control trial so far to look at advanced pneumatic compression therapy for lymphedema tied to head and neck cancer. According to what we found, Flexitouch produced outcomes reported by patients that were on par with care guided by a therapist in a population that had not previously received treatment, and it showed a robust safety profile along with benefits that held up across the six-month duration of the study. In our view, these results carry real clinical significance, since a large number of head and neck lymphedema patients encounter obstacles when trying to obtain lymphatic massage therapy — among them the burden of travel, the expense, and waiting for care. An advanced pneumatic compression option that can be used at home might help close that gap in access and make it possible for this underserved group to receive care sooner. Now that this publication is out, we will keep focusing on translating the evidence into broader awareness among providers and greater engagement with payers. I should point out that the NCD policy wording already allows advanced pumps to be covered for patients dealing with head and neck lymphedema. After that publication becomes available, we'll pivot our efforts to working alongside commercial payers so those restrictive experimental and investigational designations get removed, allowing coverage rules to reflect the growing body of clinical evidence. Our view is that this represents a deliberate, evidence-driven effort aimed at expanding awareness, improving access to care, and fostering broader adoption over time. Now, moving on to the topic of expanding treatment options, we've got some exciting news to share. Back in July, we made public an exclusive distribution deal for the U.S. with ElastiMed to bring MyoSleeve to veterans, those on active duty, and other beneficiaries receiving care through the Department of Defense. MyoSleeve is a lower-leg compression device that's wearable, non-pneumatic, and discreet. For patients whose chronic swelling hasn't progressed as far, it gives them one more choice — and at that point, staying consistent with therapy is what matters for slowing how the disease advances. Not every person responds to compression therapy in the same manner. When clinicians can pick from multiple treatment options and match them to things like a patient's stage of disease, lifestyle, anatomy, and clinical needs, that's genuinely useful. Everyday life is what this device was designed to slip into without hassle. Wearing it beneath their clothes means patients receive therapy while going about their usual routines, resulting in a compression solution that's both more discreet and more adaptable. MyoSleeve relies on electroactive polymer technology to deliver dynamic compression. Flexible bands contract one after another to make that happen. The whole system runs on batteries, so there's no tubing, no cords, and no external controller required. Just as important, it can operate in active mode and passive mode alike. That versatility lets patients follow their own preferences, which helps drive sustained adherence and engagement with treatment over time. Adding MyoSleeve extends our portfolio of lymphatic care solutions, already the market leader, and it's a natural fit for the VA channel, since we've never historically had a basic compression offering there. The design targets lower leg patients at an earlier point in the care continuum — people who may not require foot or knee coverage, or the more advanced features a pneumatic compression device brings. So for that reason, we view MyoSleeve as something that works alongside our pneumatic compression therapies, such as Flexitouch, instead of taking their place. Our plan is to leverage the VA relationships we've already built, along with our know-how in reimbursement and the infrastructure we have for supporting patients, in order to bring MyoSleeve to market. Even though uptake will likely happen slowly over time, we think this product expands the number of patients we can reach through the VA channel and advances our approach of offering complete solutions spanning the lymphatic care continuum. We're eager to provide additional updates as we continue with commercialization. Finally, our third strategic priority involves boosting the value we deliver to patients over their lifetime. Just like in earlier updates, we're continuing our focused efforts around care navigation, which are designed to give patients better direction sooner and reduce administrative headaches. Our expectation is that integrating this effort into the referral-to-ship workflow is going to cut down on patient leakage, improve how patients experience the process, and eventually lessen the amount sales reps need to be involved in handling orders, which will help drive both growth in referrals and operating leverage; so with that, I'll turn things over to Elaine, who will walk through our Q2 financial results in greater detail and give an update regarding what we're projecting for 2026.
Thank you, Sheri. Except where we say otherwise, every figure for the second quarter's financial performance is presented on a GAAP basis and compared with the same period a year earlier. During the quarter, both revenue and profitability came in above what we had anticipated, powered by ongoing momentum in our lymphedema business and by disciplined execution throughout the company. Second quarter total revenue rose by $6.8 million, which is 9%, reaching $85.7 million, again powered by ongoing momentum in our lymphedema business. Looking at product lines, sales and rentals of lymphedema products — a category that includes our Flexitouch, Nimbl, and LymphaTech systems — grew $7.7 million, or 12%, to $73.6 million. Revenue from our airway clearance lineup, which includes the AffloVest system, declined by $0.9 million, a 7% drop, landing at $12.1 million. That dip mirrors short-term inventory management patterns connected to rolling out our next generation AffloVest system with a handful of DME partners over the quarter. Turning now to profitability: gross margin reached 76.3% of revenue, compared with 74.5% during the second quarter of 2025. This margin gain stemmed primarily from reduced manufacturing costs, improved collections as reflected in revenue, and beneficial mix effects. Operating expenses for the second quarter climbed $3.8 million, up 7%, totaling $58.5 million, reflecting ongoing strategic investments aimed at supporting long-term growth, among them spending on our commercial organization, technology initiatives, and operational capabilities. When you look at the movement in GAAP operating expenses, three items account for it. Sales and marketing was up $2 million, research and development was up $0.5 million, and reimbursement, general, and administrative rose $1.3 million — that last category largely reflecting strategic investments. On the income side, operating income improved by $2.7 million, which works out to 67%, bringing it to $6.9 million. Interest income declined $0.3 million, or 34%, landing at $0.6 million, which happened because our cash position got smaller. Interest expense dropped $0.4 million, a 95% decrease, down to $19,000. We recorded an income tax benefit of $0.4 million, versus income tax expense of $1.3 million in the prior period. Net income came in at $7.8 million, up $4.6 million or 142%, equal to $0.34 per diluted share, compared with $3.2 million, or $0.14 per diluted share. On an adjusted EBITDA basis, we came in at $11.4 million, which is up 49% from $7.7 million during the same period a year ago. That improvement was powered by growth in revenue, an expansion of gross margin, and careful control of expenses. Turning to the balance sheet, at the close of the quarter we held $69.9 million in cash and cash equivalents, with no borrowings outstanding. At December 31, 2025, the figures stood at $83.4 million in cash, again with nothing outstanding on the borrowing side. The quarter's cash reduction is mainly tied to the upfront payments we made to ElastiMed so we could lock in exclusive distribution rights for MyoSleeve across the VA and Department of Defense, along with share repurchases we finished during the quarter through our repurchase program. If we set aside fresh strategic allocations of capital, the quarter saw us bring in more cash from operations than we spent, and the strength of our balance sheet keeps giving us substantial room to fund expansion and deliver returns to those who own our stock. Shifting now to how we see 2026 shaping up. Across the entire twelve months of 2026, we're revising the targets we've given and our current projection for total revenue sits between $360 million and $366 million — which works out to roughly 9%-11% higher than the prior year. Breaking that down by individual product line, the low double-digit range still reflects what we anticipate for lymphedema revenue growth over the full year, while airway clearance revenue is now tracking toward something much closer to level on a year-over-year basis. That outlook captures the ongoing momentum in our lymphedema business along with a short-term effect from the inventory management dynamics in the airway clearance channel during the second and third quarters, which Sheri covered earlier. To help with modeling for the full year 2026, we anticipate GAAP gross margins of 76%-76.5%, GAAP operating expenses rising 10%-12% versus the prior year as we annualize our investments in the sales organization and move forward with our tech-related investments over the course of the year, net interest income of roughly $2.4 million, a 28% tax rate, and a fully diluted weighted average share count of about 23 million shares; our expectation for adjusted EBITDA in 2026 remains approximately $49 million — $51 million. Even though we're pleased with the profitability we saw in the first half, leaving our guidance as is shows we're weighing things evenly — the short-term shifts in airway clearance inventory, the change in Medicare prior authorization, and the money we continue putting into initiatives for strategic growth. Within our adjusted EBITDA projection, we've accounted for several non-cash items: roughly $8.6 million in stock compensation expense, about $4.2 million in intangible amortization, approximately $3.3 million in depreciation, around $1 million tied to litigation, and $1.3 million in one-time costs from acquisition and integration. That said, I'll turn things over to Sheri for her closing comments. Sheri?
Elaine, thank you. We feel our Q2 results on both the top and bottom lines underscore how strong and resilient our business model is — we're expanding. Our profitability picture keeps getting better, and we've got the financial room to keep putting money into opportunities that could further bolster our long-term growth trajectory, all while staying disciplined about how we execute. Our priorities haven't changed: making care easier to access, widening the range of treatment choices, and building lifetime value by improving the patient experience. Once these strategies reach scale, they'll fuel growth via market leadership, market development, and operational excellence. In particular, LymphaTech extends our platform throughout the lymphedema care continuum, covering upstream diagnosis and monitoring as well. The next generation AffloVest system underscores our dedication to innovation in airway clearance. Thanks to our MyoSleeve distribution agreement, we're broadening our portfolio by adding another treatment option for veterans, active duty service members, and their beneficiaries via the Department of Defense. Our clinical evidence and payer strategies will help broaden access to care for underserved patient populations, and our order operations transformation will keep unlocking leverage and referral expansion. Tactile is well-positioned to deliver sustainable, profitable growth and generate meaningful long-term value for our shareholders. I'd like to thank the Tactile Medical employees for everything they do for patients, our clinical customer, and one another. With that, Operator, let's now open the call for questions.
Hello, Kyle Winborne here, filling in for Adam. We appreciate you fielding our questions. I suppose I'll begin with lymphedema. Results were solid during that period. Perhaps regarding those prior authorization changes you mentioned. With how things performed and the momentum behind it, it appears some of the capacity to steer through that disruption might have been balanced out by strength from the core business's own trajectory. I'm asking since, three months ago, there was considerable conversation regarding Q1 sales acceleration and possibly revenue moving into Q3 away from Q2 because of prior authorization mandates. I'm wondering whether you might put numbers to any order and revenue movement across those periods, so we could perhaps understand what typical ordering looks like. Since that period delivered such strong results, was it simply that these issues proved less widespread than people worried, or did your staff's familiarity with this procedure effectively guide you through it?
Yes, I appreciate that inquiry. Several points. Lymphedema clearly served as the main source of the beat, plus we keep witnessing exceptionally robust implementation throughout our commercial team, which includes favorable referral patterns. Our territory efficiency has gotten better, along with ongoing Flexitouch uptake propelled by the NCD. Keep in mind we began bringing our policy into line with that NCD revision during November last year. We brought on more sales representatives, meaning additional referrals are arriving. That efficiency is taking place. Every one of these factors genuinely fed into that total expansion. Certainly, Medicare's prior authorization, which we disclosed during Q1, created a scheduling effect on whenever we anticipated those orders to come through, since there was greater administrative effort required initially. Yet that is becoming increasingly normalized at this point. We're beginning to observe precisely what we anticipated, with the MACs moving closer together regarding how they handle determinations; we felt quite proud of the way our staff built up our competencies, and we're noticing the MACs likewise beginning to allocate the resources they require on their end. Thus it truly resulted from favorable referral patterns, territory efficiency, Flexitouch uptake propelled by the NCD, and what we anticipated regarding that prior authorization for Medicare. We are extremely, extremely happy with how lymphedema turned out.
All right, that's useful. So perhaps staying with the lymphedema segment and this fresh distribution deal with ElastiMed — I was hoping to gain a clearer picture of how it slots into the business model and what sort of effects we ought to anticipate for our models. From what I gather, it appears there's a commitment involving minimum purchase agreements, plus marketing and sales promotion. Would it be reasonable to look for some extra OpEx stemming from this arrangement, or, since your infrastructure is already in place, is this genuinely more of a plug-and-play situation? What might we anticipate regarding revenue impact? Apologies if I overlooked any timing details about when a contribution could be expected. Thanks.
Yes, thank you. I'll take your final question first. Over time, we view MyoSleeve as an incremental growth contributor inside the VA channel; however, no material contribution from MyoSleeve is assumed in our current guidance. That handles the revenue portion of your question. On the opex side, what we genuinely appreciate about this arrangement is that our existing infrastructure is being leveraged. The VA is already a call point for us; our reps are already very talented. Naturally, they call on every call point, yet relationships within the VA are already established. Selling across multi-provider specialties in the VA with Flexitouch is already familiar to them. With MyoSleeve, they now gain another chance to go in carrying a broader portfolio, essentially drawing on the same talent already present in our current sales force. Leveraging the resources already at our disposal is something we're truly excited about, and that's what made the VA such a strong starting point for introducing that product.
That's helpful. Thank you.
Yeah, thank you.
Thanks, and good afternoon. Turning to how airway clearance is moving, I'd like to go a bit deeper on that. What causes the ordering patterns to return to normal during Q4? And when? What are you observing at present regarding inventory levels that have to be worked through or burned down? At what point does the effect of the new AffloVest product begin to show up?
Yes, hello Ryan, and I appreciate the question. When you look at it dynamically, rolling out our next-generation product isn't all that complex, though it does push our partners to examine their total inventory position. As they prepared for this new launch, they spotted — and we spotted alongside them — that certain partners were holding excess stock, so the situation was quite constrained, meaning they have to work that stock down before resuming their usual ordering behavior. We understand what that stock looks like, and we've factored it into our back half guidance. That's the reason we're stating that we expect Q3 to be when they begin working through that inventory, and then come Q4, they'll begin returning to their typical ordering cadence. We're confident we now have solid visibility into present inventory levels. We understand what standard purchasing behavior looks like. This business can get a bit uneven around factors beyond our control, such as cold and flu seasonality and somewhat around patient affordability dynamics. Still, at this moment, reimbursement is quite steady; this really is a short-term, one-time type of situation tied to the arrival of a new product. When it comes to Gen 6, our next generation offering, our DMEs are genuinely thrilled to be delivering this to patients. Keep in mind, no additional reimbursement comes with it; it's simply an improved product building on what was already the finest product available on the market. So it features size adjustability, which is excellent; it's even lighter than what we currently offer. It's still the sole untethered vest available out there, and it now provides connectivity. So our DME partners are eager to get this to patients. They simply have to deplete some inventory at a handful of our partners across a few of their branches, and after that we'll be right back to precisely where we want to be come Q4 with standard ordering patterns.
Alright. Perhaps to go a bit deeper on the guidance, Sheri, Elaine, if you unpack the pieces, I appreciate the color you provided for the double-digit lymphedema growth, but I just want to probe that. Is any contribution from LymphaTech included in there? Then, arguably, by how much are you lowering the airway clearance guidance? If it's $1 million overall at the midpoint, is there any incremental contribution, say, from LymphaTech that might be offsetting that incremental airway clearance revenue?
Right. So LymphaTech is already part of the total guidance that gets captured when we discuss how the lymphedema business is doing. That said, we'd note LymphaTech remains a very small piece of the larger lymphedema growth we're seeing. Once again, that expansion is really driven by strong referral trends; we're pleased with the momentum there. We also like the territory productivity we're seeing. And then this NCD-related shift in alignment is genuinely supporting our broader Flexitouch adoption. So all of those things sit squarely among the strengths of the lymphedema business, and that's the reason we feel confident we'll deliver within that low double digit growth. Regarding AffloVest, it's simply that, based on what we know today, our philosophy has been to make the call using current information, and we believe ordering patterns will normalize again in the back half of the year. That's why we adjusted only the top end, while keeping the bottom end of the total guide.
Alright, that's reasonable. Let me just slip in one very small question. You mentioned that the lymphedema business faces a near-term moderation starting in 2Q, purely due to the prior auth requirement. Can you quantify that, Elaine — specifically what you might or might not recover because of it, possibly in 3Q?
My view is that the optimal lens here — and this is visible in the filing we submitted — is that during the quarter, our Medicare segment posted a decline.
Correct.
What we're discussing is exactly what that showed, since normally we wouldn't anticipate seeing something like that. Our point, I believe, is that as time goes on, we expect things will begin returning to normal. Looking at it quarter over quarter, as I think we've said previously, the expectation still stands that sequential growth in Q3 will land on the larger end relative to earlier years, closer to what happened last year. Consider how we saw that sizable jump upward, and that's essentially the shift in timing we've been describing, moving from Q2 into Q3, tied to Medicare.
Thank you.
Thanks, Ryan.
Hi, everybody. Appreciate you taking my question. I'd like to stay on AffloVest for now. Could you possibly share a bit about sell-through compared with sell-in to the channel, simply so we can better gauge what end market demand looks like? Is it still expanding at the same pace as the market? Could you put a number on it, or would you at least be willing to discuss it briefly?
Of course. On the positive side of things with AffloVest, and I realize it might not come across as positive, but let's frame it properly. What we're seeing is a short-term situation, and it came about because we rolled out a new product. This happens often with DMEs. Any time a next-gen product is on the way, or a manufacturer is upgrading or essentially swapping out a platform, they usually go back and review what they already have on hand, so they can figure out their purchasing behavior. It's an unavoidable consequence of bringing a new product to market. We're genuinely thrilled for patients and clinicians alike to be offering a strong product; it's simply an unfortunate result that accompanies it. That said, once more, it's short-term and it's very much limited to a handful of our biggest DMEs. Broadly speaking, from the market's perspective, nothing is shifting. We keep observing growth in the market. Awareness of the disease state is rising, and we already hold the market-leading product, and we're introducing an even superior product through the connectivity, the sizing adjustment, plus being even lighter; so we have a lot of confidence in this business. It's an excellent business for us. The patients are out there. The clinicians are extremely enthusiastic about this next-gen product. It's a profitable product for us. It's a healthy piece of our overall business, and we will move beyond this one-time short-term situation, once again, caused by the introduction of a new product.
Understood. All right, appreciate it. I might pose a couple of questions about reimbursement, or perhaps market access, and I'll combine them into one here. First off, the fresh six-month head and neck findings are now out. Congratulations. So what comes next? Which timeframes should we be watching for so that private-side market access can improve? For the second market access item, could you expand a bit more? As I recall, you were applying AI in-house to boost market access on the Medicare side, I believe that was it. Just elaborate a little on how those AI initiatives are progressing and how those patterns are carrying into the remainder of the year. Thank you.
Yes, appreciate the question. Both of these are topics I enjoy discussing. It's thrilling for us that the head and neck publication with six-month data is at last in an excellent peer-reviewed journal, and we're keen to put it before payers and clinicians alike so they can witness the advantage. Once more, Flexitouch against usual care. Once more, this involved treatment-naive patients. These are individuals who had never gotten even conservative care, and demonstrating the strong Flexitouch advantage in outcomes while maintaining those results at two, four, and six months will reveal considerable benefit, from the payer perspective as well as for clinicians and patients; we had already been in discussions with payers to present the 2-month data we possessed, informing them that the six-month manuscript was coming. Now it's here. We're once again meeting with payers at this moment, and we're requesting two items. We're requesting prompt reconsideration of their existing E&I policy. Should they decline a prompt reconsideration, at minimum get it onto the docket for whenever they refresh their coverage policies. That's happening right now, and our discussions are going well, and we genuinely believe the heft of this evidence will prove quite useful. What's beyond my control is their schedule. We can assist in building the argument; we can discuss it from a patient advocacy angle. The data is there to back it up, yet in the end, it's the payer's call regarding when that policy gets changed. I say when they change it since I anticipate they will change it, but that schedule is difficult; we're pursuing it quickly. Just don't anticipate payer coverage shifting right away. It does require time. I'd also like to remind everyone that the Medicare NCD already permits head and neck patients to obtain a product. This is only in the commercial space, purely commercial, plus Medicare Advantage plans that must alter their policy. Commercial Medicare fee-for-service already permits this route. With luck, then, the publication will simply assist in driving that clinician awareness toward identifying additional patients. Regarding your second inquiry, which concerned artificial intelligence and operations: what stood out to me is that operations barely came up during this earnings call. Ideally, that gets taken as a good sign. Things are progressing quite nicely in our operations, in how we bring in AI and technology, and in our tech transformation. We keep working alongside AI partners, searching for methods to make the work more efficient, to remove the sticking points when documents travel from the physician into the order management process, and those efforts keep going very well. Once there's something material to share, we'll give you an update, but it's going really well, and we're happy with how we're using both the technology we already have and the technology still to come, which will make this part of the journey a bit simpler for providers, simpler for us, and ideally speed up patients' access to the therapy. Thank you, Brandon.
Afternoon. Appreciate you taking my question. Maybe just one more regarding AffloVest. From what you're saying, it involves a small number of distributors or DMEs. Could you possibly tell us what portion of AffloVest revenue comes from the upper half of DMEs compared with the lower half of DMEs you work with? I'm simply trying to figure out if that's 60% or 90%. How do sales volumes break down across these locations?
Of course. Ben, the number exceeds 1,000. Many DMEs exist out there; our focus, which we've stated publicly, has been squarely on the 10 largest DMEs measured by volume. To repeat, these are respiratory DMEs, meaning their specialty is respiratory solutions for patients suffering from respiratory illnesses. We reach out to those outside the top 10, or we provide support to them. With our 20 account managers, our attention goes to those top 10 DMEs. More specifically, when it comes to individual DMEs, their inventory management policies differ. Certain ones are extremely meticulous, while others respond to a triggering event by, so to speak, reevaluating and tidying things up. The most I can offer here is that only a very small number of partners are involved, yet they're bigger partners, since that's where we concentrate. The positive aspect here is that we now enjoy considerable visibility. Previously we lacked that under an indirect model. There's far greater insight into the inventory those partners hold, and they're just as keen as we are to ensure that inventory keeps flowing so they can welcome the next group of patients during the upcoming cold and flu season with our next gen product. I hope that answers your question.
No, that's logical. From your 10th DME to the first DME, it doesn't sound like the gap mirrors what you'd see between the first and the thousandth DMEs available on the market. Those are pretty strong sellers right from the start.
That's right.
Understood.
Right. So, this isn't stock that we were forcing out into the channel. It really is the DME partners. Each one handles their own stock in a different way, which is why you don't see this everywhere. It isn't widespread among all DMEs. It's quite concentrated, sitting with a handful of our bigger partners. We're collaborating with them. Everyone knows what stock they're holding. After that, in line with our guidance and what we laid out in the script, we're keen to get through Q3 by using up their existing inventory, tying that to patients, and then beginning to bring order patterns back to normal starting in Q4.
That's definitely helpful. I think I got it. On LymphaTech, you got the FDA submission in, you're working on getting a CPT Category III code. Once you get kind of those things in place, what's the plan to take this thing out there more broadly?
Yeah. Right now, we're focused on achieving a more complete integration. At present, the offering goes to market as SaaS, mostly to oncology centers. However, we keep evaluating that wider possibility at a scale where 20 million patients are presently undiagnosed, and such patients aren't only located in oncology — they're also found in vascular, they're in the VA, they are with therapists. Securing the FDA clearance as a diagnostic aid will represent a truly crucial initial move toward us being able to market an objective tool for clinicians that assist in identifying those patients. After that, with the CPT3 code, there are multiple steps, yet it certainly begins that wider route toward reimbursement coverage. Beginning to monitor the code helps to somewhat bolster the broader reimbursement payment, and so on. Obtaining the clearance on the diagnostic aid is our initial move. Yet we keep evaluating the wider integration and figuring out what will be the optimal move for commercialization.
Understood. And one last thing, very briefly regarding account managers and the territories for the field sales force. Compared with the prior quarter, it appears the number of account managers is slightly lower this quarter. Could you just outline the plans as we head toward the close of the year, and then anything you could offer about what that might look like in 2027?
Yes. Here's the thing — versus what we shared in Q1, we are lower by just 2.
Oh, that was my mistake.
Right. No, it's fine. What I'd describe as flat. On any particular day there will be some variation, and you'll see a small amount of movement; even so, we remain strongly dedicated, and we've observed considerable stabilization within that model of one territory manager for each product specialist. So our position is solid. Once more, as I noted, we're glad to see that the business's strength during Q2 truly showed a rise in referrals overall along with the productivity coming from that go-to-market investment in 2025, the team maturing, and their adoption of the CRM tools. So that area is fine, and at this ratio we intend to stay. Where territory growth might create an opportunity, we'll keep assessing focused additions. But at present our attention is squarely on ensuring we get the most from both our personnel and the tools at our disposal.
All right, excellent. I appreciate you answering our questions, and congratulations on both the quarter and the headway you've made.
Thanks, Ben.
That wraps up the Q&A portion. Everyone, we appreciate your joining us, and that brings today's teleconference to a close. Please feel free to hang up your phones, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tactile Systems Technology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Tactile Systems Technology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.